{"schema_version":"secwatch.filing_event.v1","accession":"0001787400-26-000012","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2026-05-12T20:04:35+00:00","discovered_at":"2026-05-12T20:06:00.295312+00:00","generated_at":"2026-05-12T21:37:11.426186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials","bullets":["Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.","Net loss $27.8M ($0.37 per basic/diluted share) for Q1 2026; R&D expense $25.0M, G&A $5.9M.","FDA agreed to protocol amendments allowing outpatient dosing in community settings, re-dosing, and adding RA to Ntrust-2.","Enrollment ongoing at 4 billion cells per dose (12B total) across Ntrust-1 and Ntrust-2 for multiple autoimmune indications.","Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001787400-26-000012","json":"https://secwatch.observer/filing/0001787400-26-000012.json","markdown":"https://secwatch.observer/filing/0001787400-26-000012.md","text":"https://secwatch.observer/filing/0001787400-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/0001787400-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/nktx-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:37:11.426186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65826f6805c06592a7a052da2a49781546cd25c0","claim":"Nkarta, Inc. reported first quarter ended March 31, 2026 results: net income $27.8 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/0001787400-26-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"$27.8 million, or $0.37 per basic and diluted share"},{"label":"EPS","value":"$0.37 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}